Key result
A 50-year-old male on chronic amiodarone therapy developed type 2 amiodarone-induced thyrotoxicosis and recurrent ventricular fibrillation, highlighting the pro-arrhythmogenic risk of this condition.
Case Report (n=1)
This case highlights the clinical challenge of managing recurrent life-threatening ventricular arrhythmias in a patient with severe heart failure and an LVAD who develops amiodarone-induced thyrotoxicosis.
Amiodarone patients may benefit from vigilant thyroid monitoring to avert proarrhythmic thyrotoxicosis; this case leaves open optimal prevention strategies.
INTRODUCTION Amiodarone is a common drug used to treat arrhythmias and its side effects are diverse. An important adverse effect is amiodarone-induced thyrotoxicosis (AIT), which can potentially lead to a pro-arrythmogenic state. There have been limited studies on the pathogenesis of how thyrotoxicosis increases the risk of ventricular arrhythmias, which causes providers to face a therapeutic challenge in patients who require this medication for the prevention of life threatening arrhythmias. This case report will present a patient with a left ventricular assist device (LVAD) who had recurrent ventricular arrhythmias on chronic amiodarone therapy in the setting of AIT.
No takes yet. Share an insight, caveat, or question.
Ashish Shah (2016) conducted a case report in Amiodarone-Induced Thyrotoxicosis and Ventricular Arrhythmias (n=1). Amiodarone was evaluated on Development of amiodarone-induced thyrotoxicosis and ventricular arrhythmias. A 50-year-old male on chronic amiodarone therapy developed type 2 amiodarone-induced thyrotoxicosis and recurrent ventricular fibrillation, highlighting the pro-arrhythmogenic risk of this condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: